Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x doplňuje sdělení Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Sb. x. s. x x. 46/2008 Xx. x. s. a xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx věcí x. 97/2012 Xx. m. x. x Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 12. listopadu 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx xxxxx Přílohy X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx1).
S xxxxx xxxxxx Přílohy I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Přílohy I xxxxxxxxx x platnost x souladu s xxxxxxx 34 odst. 3 Úmluvy xxx 1. ledna 2013 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x pro Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I Mezinárodní xxxxxx proti xxxxxxx xx xxxxxx xxxxxx xx 1. ledna 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Přílohy I x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena pod č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2013
XXXXXXX ANTIDOPINGOVÝ XXXXX
Xxxxxx od 1. xxxxx 2013
Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx za "Specifické xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, S4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(PŘI XXXXXXX X MIMO XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX LÁTKY
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, zahrnující:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; mestanolon; mesterolon; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxx** AAS, pokud xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx x isomery, xxx ne x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx modulátory androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.
| &xxxx;
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx xxxx xxxxxxxxxx přirozeně.
|
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (např. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Růstový xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx faktory (XXXx), xxxxxxxxxxxx růstový xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx faktory (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), stejně xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, regenerativní xxxxxxxx nebo xxxxxxxxxxx xxxx svalových xxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.
S3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 xxxxxxxx včetně xxxx případných xxxxxxxxx xxxxxxx (xxxx. d- x l-), xxxx xxxxxxxx kromě xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx podány x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx salbutamolu x xxxx v koncentraci xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx v moči x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, pokud sportovec xxxxxxxxx kontrolovanou farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx xxx způsoben xxxxxxxx terapeutické xxxxxxxxx xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx xxxxx na xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
b) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx proliferátory /Peroxisome Xxxxxxxxxxxx Activated Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx xxxxxxxxxx XXX x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. DIURETIKA X OSTATNÍ MASKOVACÍ XXXXX
Maskovací látky xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x podobnými xxxxxxxxxxxx účinky. Lokální xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxx není xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx dorzolamidu x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Soutěži, případně Xxxx Soutěž) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx prahovým limitem (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx látku xxxxx x xx, xxxxx xxx byla xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
X1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx podobných produktů xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, zahrnující modifikované xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), ale xx x xxxxxxxx xxxxx xx xx. Suplementace xxxxxxxx zakázána xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx následující:
1. Xxxxxxxxx, nebo xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx je xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x omezením xxxxx xx xx.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 hodin xxxx xxxxxxxx kromě xxxxxx legitimně xxxxxxxxx x xxxxxxx nemocničních xxxxxxx nebo klinických xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Transfer nukleových xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk;
|
LÁTKY X XXXXXX ZAKÁZANÉ XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx X5 a X1 až X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx všech jejich xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- a x-) jsou xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx rok 2013*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx výslovně uvedeno x xxxxx xxxxxxxx, xx Specifickou látkou.
(x) Specifická stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx a xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Lokální xxxxxx xxxxxxxxxx (např. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx společně x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx je xxxxxxxx xxxxx při xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší xxx 10 xxxxxxxxxx v 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx v moči xx vyšší než 150 xxxxxxxxxx na xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, diamorfin(heroin), xxxxxxxx a xxxx xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, konopí x xxxxxxxxx) xxxx syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ x XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
XXXXX ZAKÁZANÉ X XXXXXXXX SPORTECH
|
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Při Xxxxxxx x následujících xxxxxxxx. Detekce xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo rozborem xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 g/l.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx zakázány xxxxx Xxx Soutěži x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx lyžích a xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x xxxxxxxxx X-xxxxx x "big xxx"
∙ Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, alprenolol, atenolol, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx xxxxx xx ně.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. m. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. m. x. xxx zrušen právním xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx xx 20.9.2014.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.